目的 分析2014—2016年遼寧省腫瘤醫(yī)院乳腺癌內(nèi)分泌治療藥物的使用情況，為臨床合理用藥提供參考。方法 對2014—2016年遼寧省腫瘤醫(yī)院乳腺癌內(nèi)分泌治療藥物的使用金額、用藥頻度（DDDs）、日均費用（DDC）及藥品排序比（B/A）進行統(tǒng)計與分析。結(jié)果 2014—2016年乳腺癌內(nèi)分泌治療藥物的總使用金額和DDDs逐年增長。來曲唑和戈舍瑞林連續(xù)3年位列銷售金額前兩名，來曲唑和他莫昔芬的DDDs始終保持在前兩位，其中來曲唑的銷售金額和DDDs連續(xù)3年居于首位，并呈上升趨勢。戈舍瑞林和依西美坦的DDC連續(xù)3年居前3位。各種乳腺癌內(nèi)分泌治療藥物的B/A值為0.5~3.5，其中B/A接近1的藥品包括來曲唑、甲羥孕酮和托瑞米芬。結(jié)論 遼寧省腫瘤醫(yī)院乳腺癌內(nèi)分泌治療藥物使用基本合理，符合安全、有效、經(jīng)濟的原則。

Objective To analyze the usage of breast cancer endocrine therapy drugs in Liaoning Cancer Hospital and Institute, and to provide reference for rational use in clinic. Methods The utilization information of breast cancer endocrine therapy drugs in Liaoning Cancer Hospital and Institute from 2014 to 2016 was extracted, and the consumption sum, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2014 to 2016, the total consumption sums and DDDs of breast cancer endocrine therapy drugs increased year by year. Consumption sum of letrozole and goserelin ranked the top two for continuous 3 years, and DDDs of letrozole and tamoxifen aways stayed in he top two. Consumption sums and DDDs of letrozole was in the first place persistently, and they had a tendency to rising. DDC of goserelin and exemestane ranked the top three for continuous 3 years. B/A of all breast cancer endocrine therapy drugs were from 0.5 to 3.5. And B/A of letrozole, medroxyprogesterone, and toremifene were close to 1.00. Conclusion The utilization of breast cancer endocrine therapy drugs in Liaoning Cancer Hospital and Institute is reasonable on the whole, according with the principle of safety, effectiveness and economy.